Biocon Limited, a prominent player in the Indian biopharmaceutical sector, has successfully completed the buyback of its Commercial Papers (CPs) worth Rs. 600.00 crores on September 19, 2025. This move demonstrates the company's strong financial position and commitment to meeting its debt obligations.

Buyback Details

The company confirmed that it has fully bought back and fulfilled its payment obligation for the Commercial Papers with ISIN INE376G14032. These CPs were originally issued on April 22, 2025, with the primary purpose of refinancing existing borrowings.

Regulatory Compliance

In a filing to the stock exchanges, Biocon Limited assured stakeholders of its compliance with regulatory requirements. The company stated:

• The CP proceeds were utilized for the disclosed purposes, adhering to the conditions mentioned in the application for listing.
• All other conditions of the offer document and CP issuance directions were strictly followed.
• The asset classification of fund-based facilities from banks and financial institutions continues to maintain its "Standard" status.
• There has been no material change in the company's financial status that could adversely affect the credit rating of the CPs.

Financial Stability

Mukesh Kamath, Interim Chief Financial Officer of Biocon Limited, signed off on the regulatory filing, emphasizing the company's commitment to transparency and financial prudence. The successful buyback and timely payment underscore Biocon's robust financial management and liquidity position.

Market Implications

This development is likely to be viewed positively by investors and stakeholders, as it reflects Biocon's ability to manage its short-term debt effectively. The company's proactive approach to debt management and regulatory compliance could potentially strengthen investor confidence in its financial stability and governance practices.

As Biocon Limited continues to navigate the dynamic biopharmaceutical landscape, this successful CP buyback serves as a testament to its financial strength and commitment to meeting its financial obligations.

Biocon Biologics, a subsidiary of Biocon Limited, has achieved a significant milestone in the Canadian healthcare market. The company's biosimilar drug Yesafili (aflibercept) has been added to Ontario's Public Drug Formulary, marking an important step in expanding access to treatment for patients with retinal diseases in Canada.

Expanded Access for Retinal Disease Patients

The inclusion of Yesafili in Ontario's public drug program is set to have a substantial impact on patient care:

• Funded Access: Patients with retinal diseases in Ontario will now have funded access to Yesafili through the public healthcare system.
• Broader Reach: This development is expected to make the treatment more accessible to a larger patient population in Canada's most populous province.
• Cost-Effective Treatment: As a biosimilar, Yesafili offers a more affordable alternative to the original biologic drug, potentially reducing the financial burden on both patients and the healthcare system.

About Yesafili

Yesafili is Biocon Biologics' biosimilar version of aflibercept, a medication used to treat various retinal conditions:

• Indications: Commonly used for age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal disorders.
• Mechanism: Works by inhibiting vascular endothelial growth factor (VEGF), which is responsible for the abnormal growth of blood vessels in the eye.

Implications for Biocon Biologics

This regulatory achievement represents a significant opportunity for Biocon Biologics:

• Market Expansion: Inclusion in Ontario's formulary opens up a substantial market for Yesafili in Canada.
• Competitive Position: Strengthens Biocon Biologics' position in the global biosimilars market, particularly in North America.
• Revenue Potential: The funded access is likely to drive uptake of Yesafili, potentially boosting the company's revenue from this product.

The addition of Yesafili to Ontario's Public Drug Formulary underscores Biocon Biologics' commitment to expanding access to affordable, high-quality biosimilars. This development not only benefits patients in Canada but also reinforces the company's growing presence in the global pharmaceutical market.